Federal Official Gazette
PERSONNEL ORDINANCE ANS No. 305, OF OCTOBER 14, 2026
To designate the civil servant VIVIANE DOS SANTOS PEREIRA, SIAPE Registration No. 3349637, to serve as occasional substitute for the Executive Commissioned Position of Deputy Director – FCE 1.16, in the Deputy Directorate – DIRAD, of the Inspection Directorate – DIFIS, during the legal, temporary and occasional absences of its holder.
ANS news
ANS holds 56th Technical Meeting of Cosaúde
The National Supplementary Health Agency (ANS) will hold the 56th Technical Meeting of the Commission for the Update of the List of Health Procedures and Events in Supplementary Health (Cosaúde) on Oct 20, from 9 a.m. to 5 p.m., and Oct 21, from 9 a.m. to 12:30 p.m. At these meetings, the Commission will analyze the contributions from society received during the social participation stage and discuss new proposals for incorporating technologies into the List (Rol) of mandatory coverage of health plans.
On Oct 20, the following will be discussed:
- UAT No. 219 – Ivosidenib: preliminary discussion for the treatment of adults with locally advanced or metastatic cholangiocarcinoma, with IDH1 R132 mutation and prior systemic treatment;
- UAT No. 205 – Cardiac contractility modulation device: analysis of the contributions received in the social participation stage;
- UAT No. 200 – Next-generation sequencing (NGS) panel: analysis of the contributions on the use of the panel to identify genetic alterations in non-small cell lung cancer; and
- UAT No. 206 – Tepotinib hydrochloride: analysis of the contributions on the first-line treatment of advanced lung cancer with a specific MET gene mutation.
On Oct 21, the following will be analyzed:
- UAT No. 216 – Lenvatinib in combination with pembrolizumab: preliminary discussion for first-line treatment of advanced or metastatic renal clear cell carcinoma; and
- UAT No. 209 – 21-gene test for breast tumor: analysis of the contributions received in the social participation stage.
Open public consultations
- CP 178. Subject matter: preliminary recommendations against the incorporation of somatrogon and cabozantinib levomalate. Deadline: October 7 to 26, 2026.
Scheduled public hearings
- AP 70. Subject matter: preliminary recommendations against the incorporation of somatrogon and cabozantinib levomalate, technologies submitted to public consultation 178. Date: Oct 16, from 9:30 a.m. to 12:30 p.m.
Open public calls for input
- The call for input addressed to the ombudsman offices of health plan operators, concerning the effectiveness of service channels and the monitoring provided for in RN No. 623/2024, is open until Oct 20.
Open public calls
There are no open public calls or targeted social participation processes.
Other news
STJ establishes qualified precedent on home-use cannabidiol
The Second Section of the Superior Court of Justice recognized the relevance of the federal question and unanimously reaffirmed its case law on the funding of cannabidiol-based medicines for home use.
The thesis establishes, in summary, that operators are not required to fund these medicines where there is no legal, contractual or regulatory provision for coverage. The exceptional import authorization granted by Anvisa, on its own, does not expand the scope of the contract or turn the product into mandatory coverage. The judgment was conducted under the summary procedure provided for in STJ Regimental Amendment No. 55/2026, with recognition of relevance and formation of the qualified precedent in the same session. There was no nationwide suspension of proceedings. The official news item did not identify the case number used for the reaffirmation.
Sources: Federal Official Gazette (DOU) and the ANS website. Press items link to the original article. This brief is for information only and does not constitute legal advice.